Antibody Drug Conjugates in Metastatic Breast Cancer | Dr.Sramila Aithal, MD US Oncology

ASCO22 Metastatic Breast Cancer Updates | Sramila Aithal, MD | US OncologyПодробнее

Dr. Sramila Aithal on the EMILIA Trial Studying T-DM1 in Metastatic Breast CancerПодробнее

Antibody Drug Conjugates in Metastatic Breast Cancer | Anthony Elias, MD | ESMO22 ColoradoПодробнее

Antibody Drug Conjugates in Metastatic Breast Cancer | Sramila Aithal, MD | ESMO22 PennsylvaniaПодробнее

Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast CancerПодробнее

Antibody-drug conjugates for the treatment of breast cancerПодробнее

Sramila Aithal, MD | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ DiseaseПодробнее

Emergence of antibody-drug conjugates in metastatic breast cancer: 2022 ESMO FloridaПодробнее

Antibody Drug Conjugates Present and Future Applications in Breast CancerПодробнее

Novel antibody-drug conjugates (ADCs) technologies for management of mBCПодробнее

Dr. Soliman the Utility of ADCs in Breast CancerПодробнее

Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast CancerПодробнее

HER2+ Breast Cancer: Evolution of Antibody-Drug ConjugatesПодробнее

Emerging Antibody-Drug Conjugates in Breast Cancer: An Expert Analysis of Promising TherapiesПодробнее

Advances in antibody-drug conjugates for breast cancer at ESMO 2022Подробнее

Dr. Cobleigh on Antibody-Drug Conjugates in Development in HER2+ Breast CancerПодробнее

Dr. Sramila Aithal on the AE37 Peptide Vaccine in Breast CancerПодробнее

Experts discuss Antibody-Drug Conjugates in Breast, Lung, & GI Cancers - https://bit.ly/3rKKvzMПодробнее

Where are we in sequencing ADCs in HR+ breast cancer?Подробнее